Epidermolysis Bullosa – Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

1.1. ReportOverview

2. Epidermolysis Bullosa - Overview

3. Executive Summary

4. Epidermolysis Bullosa : Pipeline Assessment (Applicable Areas ofAssessment)

4.1. By Stage ofDevelopment

4.2. By Route ofAdministration

4.3. By DrugClass

4.4. By MoleculeType

4.5. By Therapy Area/ Indication

4.6. By DrugTarget

4.7. By Sponsor

5. Epidermolysis Bullosa: Company & Drug Profiles

5.1. ClinicalStage

5.1.1. AC-203 – TWi Biotechnology, Inc.

5.1.1.1. Company Overview

5.1.1.2. Product Description

5.1.1.3. R&D Status & Development Activities

5.1.1.4. Mechanism of Action

5.1.1.5. Molecule Type

5.1.1.6. Stage of Development

5.1.1.7. Indications

5.1.1.8. Route of Administration

5.1.1.9. Funding

5.1.2. URGO AWC_019 – Laboratoires URGO

5.1.2.1. Company Overview

5.1.2.2. Product Description

5.1.2.3. R&D Status & Development Activities

5.1.2.4. Mechanism of Action

5.1.2.5. Molecule Type

5.1.2.6. Stage of Development

5.1.2.7. Indications

5.1.2.8. Route of Administration

5.1.2.9. Funding

5.1.3. Oleogel-S10 – Amryt Pharma (Birken AG)

5.1.3.1. Company Overview

5.1.3.2. Product Description

5.1.3.3. R&D Status & Development Activities

5.1.3.4. Mechanism of Action

5.1.3.5. Molecule Type

5.1.3.6. Stage of Development

5.1.3.7. Indications

5.1.3.8. Route of Administration

5.1.3.9. Funding

5.1.4. Others

5.2. Preclinical

5.2.1. Company Overview

5.2.2. Product Description

5.2.3. R&D Status & Development Activities

5.2.4. Mechanism of Action

5.2.5. Molecule Type

5.2.6. Indications

5.2.7. Route of Administration

5.2.8. Funding

6. Epidermolysis Bullosa: An Overview on Dormant & DiscontinuedPipeline Candidates

6.1. Overview

6.2. ProductDescription

6.3. Reason forDiscontinuation

7. Epidermolysis Bullosa: Additional Key Insights

7.1.Epidemiology Overview: Epidermolysis Bullosa

7.2. CurrentMarket Scenario: Epidermolysis Bullosa Therapeutics

8. Epidermolysis Bullosa: News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.